Meeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: 501 Authors: Robert E. Coleman, Dianne Finkelstein, Carlos H. Barrios, et. al. Background: Denosumab (Dmab) is a potent RANK ligand inhibitor approved for the management of treatment induced bone loss in early breast (EBC) and prevention of skeletal morbidity associated with...
Pro zobrazení tohoto obsahu je třeba být přihlášen.